News
Archive
Finally, Graphene electronic devices available for all
Ventyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event
NorthSea Therapeutics initiates Phase 2A trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
Resolve Therapeutics announces publication of Lupus clinical trial results
biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC
InvestEU in Belgium: EIB venture debt for bone therapy innovator Novadip
Back To NewsMay 11, 2021
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.